Literature DB >> 18344628

Angiotensin II receptor blocker reduces oxidative stress and attenuates hypoxia-induced left ventricular remodeling in apolipoprotein E-knockout mice.

Chika Yamashita1, Tetsuya Hayashi, Tatsuhiko Mori, Naoko Tazawa, Chol-Jun Kwak, Daisuke Nakano, Koichi Sohmiya, Yoshikatsu Okada, Yasushi Kitaura, Yasuo Matsumura.   

Abstract

Elevated superoxide formation in cardiac extracts of apolipoprotein E-knockout (apoE-KO) mice has been reported. In addition, we previously reported that hypoxia increased oxidative stress in the aortas of apoE-KO mice, although we did not examine the effect of hypoxia on the heart. The aim of this study was to investigate the effect of chronic hypoxia on the left ventricular (LV) remodeling in apoE-KO mice treated with or without an angiotensin II receptor blocker. Male apoE-KO mice (n=83) and wild-type mice (n=34) at 15 weeks of age were kept under hypoxic conditions (oxygen, 10.0+/-0.5%) and treated with olmesartan (3 mg/kg/day) or vehicle for 3 weeks. Although LV pressure was not changed, hypoxia caused hypertrophy of cardiomyocytes and increased interstitial fibrosis in the LV myocardium. Furthermore, nuclear factor-kappaB (NF-kappaB) and matrix metalloproteinase (MMP)-9 activities were increased in apoE-KO mice exposed to chronic hypoxia. Olmesartan effectively suppressed the 4-hydroxy-2-nonenal protein expression and NF-kappaB and MMP-9 activities, and preserved the fine structure of the LV myocardium without affecting the LV pressure. In conclusion, olmesartan reduced oxidative stress, and attenuated the hypoxia-induced LV remodeling, in part through the inhibition of NF-kappaB and MMP-9 activities, in apoE-KO mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18344628     DOI: 10.1291/hypres.30.1219

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  12 in total

1.  Effect of Telmisartan on local cardiovascular oxidative stress in mouse under chronic intermittent hypoxia condition.

Authors:  Wan-Yu Wang; Wan-Yu Wan; Yi-Ming Zeng; Xiao-Yang Chen; Yi-Xiang Zhang
Journal:  Sleep Breath       Date:  2012-03-25       Impact factor: 2.816

2.  Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.

Authors:  Chetan P Hans; Yumei Feng; Amarjit S Naura; Dana Troxclair; Mourad Zerfaoui; Danish Siddiqui; Ju Jihang; Hogyoung Kim; Alan D Kaye; Khalid Matrougui; Eric Lazartigues; A Hamid Boulares
Journal:  Cardiovasc Pathol       Date:  2010-05-07       Impact factor: 2.185

3.  Initial reduction of oxidative stress by angiotensin receptor blocker contributes long term outcomes after percutaneous coronary intervention.

Authors:  Tadanori Noro; Naofumi Takehara; Kazuhiro Sumitomo; Toshiharu Takeuchi; Yoshinao Ishii; Jun-Ichi Kato; Jun-Ichi Kawabe; Naoyuki Hasebe
Journal:  Am J Cardiovasc Dis       Date:  2014-12-29

4.  Olmesartan reduces arterial stiffness and serum adipocyte fatty acid-binding protein in hypertensive patients.

Authors:  Toru Miyoshi; Masayuki Doi; Satoshi Hirohata; Shigeshi Kamikawa; Shinichi Usui; Hiroko Ogawa; Kosuke Sakane; Reishi Izumi; Yoshifumi Ninomiya; Shozo Kusachi
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

5.  Angiotensin II and the ERK pathway mediate the induction of myocardin by hypoxia in cultured rat neonatal cardiomyocytes.

Authors:  Chiung-Zuan Chiu; Bao-Wei Wang; Tun-Hui Chung; Kou-Gi Shyu
Journal:  Clin Sci (Lond)       Date:  2010-06-22       Impact factor: 6.124

Review 6.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 7.  Olmesartan medoxomil: a review of its use in the management of hypertension.

Authors:  Lesley J Scott; Paul L McCormack
Journal:  Drugs       Date:  2008       Impact factor: 9.546

8.  Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial.

Authors:  Toru Miyoshi; Atsushi Hirohata; Shinichi Usui; Keizo Yamamoto; Takashi Murakami; Issei Komatsubara; Shozo Kusachi; Tohru Ohe; Kazufumi Nakamura; Hiroshi Ito
Journal:  Heart Vessels       Date:  2013-04-07       Impact factor: 2.037

9.  Enalapril mitigates radiation-induced pneumonitis and pulmonary fibrosis if started 35 days after whole-thorax irradiation.

Authors:  Feng Gao; Brian L Fish; John E Moulder; Elizabeth R Jacobs; Meetha Medhora
Journal:  Radiat Res       Date:  2013-10-18       Impact factor: 2.841

10.  Regulation of oxidative stress and cardioprotection in diabetes mellitus.

Authors:  Tetsuya Hayashi; Tatsuhiko Mori; Chika Yamashita; Masatoshi Miyamura
Journal:  Curr Cardiol Rev       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.